Summary Recent arouse of interest indicated that drug resistant proteins are markedly over-expressed in the epileptogenic tissue and they may be responsible for the one-third of the epileptic patients who were refractory to anti-epileptic drugs (AEDs). Since several AEDs may act as substrates for these drug resistant proteins, the enhanced function of such proteins may increase drug extrusion, resulting in inadequate response to drug therapy in patients with epilepsy.
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Summary Recent arouse of interest indicated that drug resistant proteins are markedly over-expressed in the epileptogenic tissue and they may be responsible for the one-third of the epileptic patients who were refractory to anti-epileptic drugs (AEDs). Since several AEDs may act as substrates for these drug resistant proteins, the enhanced function of such proteins may increase drug extrusion, resulting in inadequate response to drug therapy in patients with epilepsy.
We studied expression of the multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 1 (MRP1) in the epileptic tissues resected surgically in 28 patients with focal cortical dysplasia (FCD) by immunohistochemistry. The results were compared with 10 normal necropsy brain tissues.
Normal brain showed no MDR1 expression in neurons and astrocytes, while MRP1 expression was very weak, which were encountered in a few samples. MDR1 expression was mainly localized on the vascular endothelial cells. In contrast to normal brain, we found intense MDR1 and MRP1 expression in both neurons and reactive astrocytes in the vast majority of dysplastic tissues. The majority of the dysplastic neurons demonstrated moderate to strong MRP1 immunoreactivity. Endothelial cells showed both MDR1 and MRP1 expression in the majority of the specimens studied.
Multidrug transporters are over-expressed in the epileptogenic zone in patients with FCD. These results are concordant with previous studies, in which over-expression of multidrug proteins were shown in epileptogenic brain tissue in patients with
Introduction
Failure to respond to the therapeutic concentrations of antiepileptic drugs (AEDs) is the usual basis for defining multiple drug resistance epilepsy, but the main mechanism(s) underlying the drug resistance to AEDs is still largely unknown. It seems likely that one possible explanation that has emerged as a credible potential factor recently is impairment of drug penetration into the brain by efflux transporters. It has been hypothesized that over-expression of efflux transporters, such as ATPbinding cassette proteins (ABC), at the bloodbrain-barrier (BBB), which prevents AEDs from reaching sufficiently high brain concentrations despite adequate plasma levels, could be one such mechanism. 1 In recent years, much attention has been focused on the mediators of multidrug resistant proteins (MDRPs) in a variety of clinical entities including some forms of cancer 2 and medically refractory epilepsy syndromes such as temporal lobe epilepsy due to hippocampal sclerosis (HS), 3 malformations of cortical development, 4 tuberous sclerosis (TS) 5 and dysembryoplastic neuroepithelial tumors (DNETs). 6, 7 Amongst the best-understood mediators of drug resistance are multidrug resistance gene-1 p-glycoprotein (MDR1) and multidrug resistance-associated protein-1 (MRP1), both of which are the members of the ABC transporter superfamily. 1, [8] [9] [10] It has been demonstrated that the brain under normal circumstances is protected by MDR1 and MRP1, which contribute to the BBB and blood-cerebrospinal fluid (blood-CSF) barrier, respectively. Such barrier transporters can specifically and efficiently remove a drug from the central nervous system, thereby limiting the accumulation of such drug in the brain. MDR1 is most probably found on the vessel endothelium, whilst MRP1 is found only in the choroid plexus epithelium in normal brain. 11 Despite advances in AED theraphy, about onethird of patients with epilepsy are resistant to drug treatment. The consequences of uncontrolled epilepsy can be severe and include shortened life span, neuropsychological impairment and social disability. Focal cortical dysplasia is (FCD) not only a congenital maldevelopment of the cortical tissue but also one of the most common maldevelopment causing refractory epilepsy. Resistant to the pharmacological treatment with broad range of AEDs is also one common characteristic feature of FCD.
Several studies demonstrating the over-expression of MDRPs in brain tissues of patients with temporal lobe epilepsy with or without HS have been reported, however; the neuronal expression of MDRPs was observed in only a limited number of patients with FCD. 6, 7, 12, 13 Therefore, this led us to investigate the best-understood mediators, MDR1 and MPR1, of drug resistance in epileptogenic tissue of the patients with FCD in a prospective study including higher number of patients than the previously reported studies. In addition, we have evaluated relationship between MDRPs and duration of epilepsy, number of AEDs, seizure frequency before and after AEDs.
Material and methods
Patients and controls
This study was performed with the collaborative effort of Neurosurgery, Neurology and Pathology departments of Istanbul University, Cerrahpasa Medical Faculty. The formalin-fixed paraffinembedded 28 human brain tissues from pathological archives were studied for detection of MDR1 and MPR1 by immunohistochemistry method. The Local Joint Ethics Committee of Istanbul University approved the study. The classification system proposed and modified by Mischel et al. 14 and Palmini et al., 15 respectively, was used for grading FCD. All patients had medically intractable epilepsy prior to surgery and had been exposed to multiple (at least two) AED and they underwent interictal-ictal video-EEG monitarization (with intracranial recordings when necessary), high resolution MRI, neuropsychological and psychiatric examination for presurgical evalution. Mean age at seizure onset was 6.27 AE 7.2 and mean duration of epilepsy was 14.57 AE 12.8 years. Table 1 summarizes the demographic data of the patients included in this study.
All patients were underwent either tailored surgical resection of the epileptogenic cortical tissues according to the intracranial recordings or lesionectomy. Complete removal was accomplished in 23 patients (82.14%) and extends of FCD, that the over-expression of drug transport proteins in tissue from patients with refractory epilepsy may explain one possible mechanism for drug resistant in these pathologies. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. resection was detected by postoperative brain MRI scans. Large dysplastic neurons, disordered laminar architecture, variable size and numbers of balloon cell often located in the deeper regions of the cortex and the underlying white matter were the main characteristic histopathological findings found in all patients. Postoperative seizure outcome was classified according to Engel. 16 The control group included 10 age-matched autopsy specimens of human brain with no history of seizures. The control specimens were obtained within 24 h following death.
Tissue preparation
All tissues studied were fixed in 10% buffered formalin and formalin-fixed, paraffin-embedded tissue was sectioned at 5 mm and mounted on organosilane-coated slides (Sigma, St. Louis, MO, USA). Neuropathological revision of the cases was performed on hematoxylin and eosin (H-E) stained sections together with Luxol fast blue and Bielschowski stained permanent sides. Neuroflament (Neu), vimentin, glial fibrillary acidic protein (GFAP), and microtubule-associated protein (MAP2) primary antibodies were used immunohistochemically for diagnosis of the different cell types. Histopathological evaluation was done according to Palmini et al. 15 The presence of cortical laminar disruption and cytological abnormalities were considered.
Group of neuronal cells which had small diameter with large nucleus and narrow cytoplasm, were found in the cortex, they were identified as immature neurons. Dysmorphic neurons were recognized as disoriented cells with abnormal shape, atypical dendritic process with clump of Nissl substance. They showed strong cytoplasmic Neu positivity. Giant neurons were bigger size neurons comparing with V layer pyramidal neurons, which had central nucleolus and showed moderate cytoplasmic Neu positivity. Ballon cells were observed if they existed in the cortex or subcortical white matter, as the cells that had eccentric nucleolus with ballooned opalescent eosinophilic cytoplasm without any Nissl substance. Some of them showed GFAP (or MAP2) but the others showed Neu immunopositivity. They were all vimentin positive.
Antibodies
For detection of MDR1 expression, monoclonal antibodies C18-0160 (1:250 dilution; Zymed Laboratories Inc., San Francisco, CA, USA) were used. They recognize the different internal epitopes of the MDR1 molecule. To detect MRP1 expression, monoclonal antibodies C18-7246 (1:100 dilution; Zymed Laboratories Inc., San Francisco, CA, USA) were used. These antibodies have been well-characterized, recognized separate internal epitopes of the MRP1 molecule. Furthermore, these are believed to be specific for MRP1, with no cross-reactivity. 
Results
When we compared the patients and controls regarding to MDR1 and MRP1 in neurons and astrocytes, statistically significant difference was found both in neurons ( p = 0.007 and 0.004 for MDR1 and MRP1, respectively) and in astrocytes ( p = 0.04 and 0.01 for MDR1 and MRP1, respectively). However, endothelial cells did not show statistically significant difference ( p = 0.34 and 0.06 for MDR1 and MRP1, respectively). Paired Student's t-test demonstrated no significant difference between the seizure frequencies before and after AEDs used ( p = 0.18). Table 2 demonstrates the results of both MDR1 and MRP1 IR in patients with FCD included in this study.
MDR1 and MRP1 expression in neurons, giant neurons, and dysmorphic neurons
Both MDR1 and MRP1 IR were encountered in the neuronal component of the majority of FCD (Fig. 1a  and b) . In 14 patients (50%) with MDR1 positive specimens, moderate (five patients, 35.7%) to strong (eight patients, 64.2%) staining was observed in the majority of the patients. In 22 patients (78.5%) with MRP1 positive staining, similarly, moderate IR was seen in 13 patients (59% Fig. 2a and b) .
When considering dysmorphic neurons, 19 patients (67.8%) were included in this group and moderate to strong MRP1 IR was noted in 14 (73.6%) patients.
No significant correlation between number of AEDs, duration of epilepsy, seizure frequency (before/after AEDs used) and MDR1/MRP1 expression in neurons, giant neurons, and dysmorphic neurons was obtained ( p > 0.05), arguing against the possibility that MDRP expression was related to seizure frequency and epilepsy duration as well.
In agreement with previous reports, antibodies directed against MDR1 demonstrated no neuronal labeling and only five showed weak MRP1 IR in control normal cortex (Fig. 3 ).
MDR1 and MRP1 expression in reactive astrocytes
Nine patients (32.1%) showed IR for MDR1 that often stained strongly (Fig. 4a) . Prominent staining of cell with reactive astrocytic morphology was demonstrated with MRP1 (Fig. 4b) . In 16 patients (57.1%), reactive astrocytes revealed moderate to strong MRP1 IR.
In control group, there was no MDR1 IR in astrocytes and weak IR to MRP1 was shown in five specimens.
No significant correlation between number of AEDs, duration of epilepsy, seizure frequency (before/after AEDs used) and MDR1/MRP1 expression in reactive astrocytes was demonstrated ( p > 0.05).
MDR1 and MRP1 expression on endothelial cells
In 15 (53.5%) and 13 (46.4%) patients, we demonstrated MDR1 and MRP1 IR in vessels within the epileptogenic zone, respectively ( Fig. 5a and b) . The vast majority of 15 patients showed prominent staining, ranging mainly from moderate to strong, with MDR1. In agreement with previous reports, this is not surprising because in normal human brain, MDR1 is found mostly in the vicinity of blood vessels, most probably on the endothelial cells. In controls, nine of 10 showed MDR1 IR that is consistent with the literature (Fig. 6 ). MRP1 staining was detectable in capillary endothelium in 13 pathological tissues. It seems to be inconsistent with the previous reports, which showed MRP1 staining in the choroid plexus epithelium only. However, the demonstration of MRP1 IR on the vascular endothelium may be related to MRP1 staining of astrocytic foot processes around the capillaries as previously described. This finding was confirmed by our control tissues, in which we showed MRP1 IR in only one specimen. No significant correlation between number of AEDs, duration of epilepsy, seizure frequency (before/after AEDs used) and MDR1/MRP1 expression on capillary endothelium was demonstrated ( p > 0.05).
MDR1 and MRP1 expression in balloon cells
Balloon cells with prominent nucleoli have been implicated in the epileptogenecity of FCD and the origin of such cells with morphological changes is still unclear. In this study, only six patients (21.4%) revealed balloon cells and there were one weak, one strong MDR1 IR (Fig. 7a) and two moderate MRP1 IR detected (Fig. 7b) .
No significant correlation between number of AEDs, duration of epilepsy, seizure frequency (before/after AEDs used) and MDR1/MRP1 expression in balloon cells was demonstrated ( p > 0.05).
Distribution of MDR1 and MRP1 according to histopathological type
The statistical analysis demonstrated no statistically significant difference between the degree of staining and the degree of histopathological type.
We were able to demonstrate the percentage of each degree of staining with respect to the degree of histopathological type (Table 3) .
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H. Ak et al. In neurons, both MDR1 and MRP1 IR were prominent in specimens with type IB and IIA In reactive astrocytes of type IIA, moderate to strong IR of both MDR1 and MRP1 were noted. MDR1 IR appeared in specimens with type IIB only, but MRP1 IR was positive in type IB, IIA, and IIB accompanied with giant neurons. In specimens contained dysmorphic neurons, marked staining of MDR1 was present in especially type IIA, whereas both type IIA and IIB demonstrated MRP1 IR. In this study six patients showed balloon cells, which are considered the hallmarks of severe architectural disorganization and are attributed to only type IIB that also showed both MDR1 and MRP1 IR.
Discussion
Although the concept of drug transporters has been originated from the researches in oncology, they have been increasingly recognized and implicated in the mechanism(s) of resistance to medical therapy in refractory epilepsy. It is conceivable to think that such drug transporters may play a role in pharmacoresistance in epilepsy, analogous to drug resistance in cancer. Tishler et al. 17 were the first to report that brain expression of MDR1 is markedly increased in the majority of patients with medically intractable partial (mostly temporal lobe) epilepsy and suggested that MDR1 may play a clinically significant role in refractoriness by decreasing the drug concentration in the brain parenchyma. Later on other groups of pathological lesions that often associated with intractable epilepsy including, FCD, 6,7,12,13 TS, 5 and DNETs 6 have been studied. FCD is a congenital maldevelopment of the cortex of the brain and one of the most common malformations causing refractory epilepsy. There have been only four reports, which demonstrated either MDR1 or MRP1 or both in epileptogenic brain tissues in limited number of patients with FCD (Table 4) . 6, 7, 12, 13 The pioneering study came from Sisodiya et al. 12 who studied four samples of surgically resected FCD and compared the findings with normal necropsy brain tissue. They demonstrated that giant dysplastic neurons showed cytoplasmic IR for MRP1 in all four cases. Three of four samples also had IR in reactive astrocytes in subcortical white matter. However, the authors were not able to demonstrate IR in balloon cells, glial components of FCD. Neurons from adjacent to and distant from the lesion did not show any IR. Furthermore, neuronal and perivascular tissues showed no immunoreactions in four age-matched normal control. This preliminary work raised the possibility that over-expression of this drug transporters, also known as brain protectors, may reduce the drug concentration by exporting the drugs from the CSF causing refractoriness in FCD. The second study was also reported by the same authors who extended their previous work 12 by increasing the number of the patients that included DNET (eight patients), HS (eight patients), and FCD (14 patients). 6 They studied IR for MDR1 in addition to MRP1 in these patients and compared them with histologically normal adjacent brain tissue. The findings confirmed their previous work that in 14 cases with FCD, both MDR1 and MRP1 expressions were noted in reactive astrocytes in all cases. IR was always more frequent and intense in lesional reactive astrocytes than in reactive astrocytes belonging to the adjacent normal tissue. Dysmorphic neurons in five and balloon cells in two cases had MRP1 expression. The adjacent normal cortex showed fewer IR for MDR1 and MRP1 and no normal neurons were labeled either with MDR1 or MRP1 antibody. Thus, they consider that MDR1 and MRP1 in reactive astrocytes and MRP1 in a few dysmorphic neurons and balloon cells in FCD may represent the over-expression of drug transporters that may lead to refractoriness in FCD.
The third study was performed by Aronica et al. 7 who studied the expression of MDR1 and MRP1 in 15 patients with FCD containing abundant balloon cells. They compared the lesional, perilesional, and normal brain tissues and found that the normal brain tissues expressed MRP1 below detection and MDR1 was mainly found on the endothelial cells. The vast majority of the patients with FCD (11 of 15) showed strong IR for MDR1, as well as MRP1. Moderate to strong MDR1 and MRP1 IR were observed in large ballooned neuroglial cells. Perilesional regions and normal brain tissues did not show IR for both MDR1 and MRP1. The authors supported the hypothesis that constitutive over-expression of MDRPs may be the common mechanism underlying the pharmacoresistance to AEDs in refractory epilepsy. The last study was performed by Marchi et al. 13 who confirmed that MDR1 was over-expressed in blood vessels, astrocytes, and neurons in dysmorphic regions extracted surgically from four patients with FCD. They further demonstrated that uptake of an AED, i.e. Phenytoin, was significantly lower in astrocytes of an epileptic brain than normal astrocytes, suggesting the limitation of the drug uptake by MDR1. The present study consisted of the largest series of patients with FCD has confirmed the findings of previous four studies which showed a remarkable expression of MDR1 and MRP1 in glial and neuronal tissue of FCD when compared with normal brain. Furthermore, we supported to the findings demonstrated in a rat model of temporal lobe epilepsy by Volk and Löscher 18 that higher expression of MDRPs was not secondary to high seizure frequency or duration of epilepsy, and it is unlikely that treatment with AEDs per se is responsible for the observed intralesional over-expression of MDRPs, which may already be present before the onset of seizure or exposure to AEDs. Although it is known that normal brain does not express MDR1 and MRP1 in neurons; over-expression of MRP1 was mainly localized in neuronal component of dysmorphic tissues. The neuronal expression of MDR1 and MRP1 were demonstrated in a large number of specimens in our study included larger population of patients with FCD than previously reported studies. Endothelial cells expressed principally MDR1 IR and in agreement with the previous studies, endothelial cells from the normal brain specimens demonstrated MDR1 IR. Thus, our results also support the current data that MDR1 are the vascular component of cortical maldevelopment. MRP1 IR in dysmorphic neurons was more abundant than MDR1. Nevertheless, findings including the present study support the current notion that MDR1 and MRP1 as drug transporters are over-expressed in epileptogenic brain regions, suggesting that they might lower local interstitial drug concentrations and thereby reduce their anti-epileptic effects, which may explain the refractoriness to AEDs in FCD.
The multidrug resistant theory in medically intractable epilepsy seems biologically plausible; however, it remains to be proved. Although, the experimental and clinical studies are still in their infancy, they are encouraging and enable us to explain at least one mechanism of drug resistance in epilepsy. However, there is still debate related to whether over-expression of drug transporters in epileptogenic tissue is intrinsic (constitutive) or induced/acquired as a consequence of epilepsy, uncontrolled seizure, chronic use of AEDs, or combination of these factors. In animal models of temporal epilepsy, a transient increase in drug transporter concentrations in astroglia, neurons and brain capillary endothelial cells following a seizure was demonstrated which suggests the seizure themselves can induce over-expression of drug transporters. 19, 20 On the other hand, constitutive rather than inductive over-expression of MDRPs has been demonstrated in patients with intractable epilepsy secondary to cortical maldevelopment and recently in a rat model of temporal lobe epilepsy. 18 Following the promising results drawn from the studies described above, one may consider that development of AEDs that bypass over-expressed MDRPs could be a valuable approach for overcoming drug resistance. For direct proof of principle, some studies used MDR1 inhibitors and demonstrated that addition of inhibitors greatly improved overall seizure control in animals 21 and in a patient who showed improved subjective quality of life. 22 Moreover, current data indicate that at least seven major AEDs including phenytoin, phenobarbital, carbamazepine, lamotrigine, gabapentin, felbamate, topiramate, are substrates for and transported by MDRPs at the BBB.
Despite current promising data, possibility of other mechanisms of drug resistance in epilepsy cannot be disregarded; therefore the practical use of MDRP inhibitors in the treatment of refractory epilepsy definitely needs further studies to prove the hypothesis.
Conclusion
Based on the largest number of the patients with FCD, we demonstrated that over-expression of the best-known MDRPs; MDR1 and MRP1 are common features of FCD. As a consequence, MDRPs may be a target to design AED treatment regimen for overcoming the drug intractability in epilepsy. However, further studies will be required to clarify the roles of drug transport proteins other than MDR1 and MRP1 for drug resistance in epilepsy.
